BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTXWGet Free Report) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 3,600 shares, a growth of 125.0% from the February 13th total of 1,600 shares. Based on an average daily volume of 90,200 shares, the short-interest ratio is presently 0.0 days.

BriaCell Therapeutics Stock Down 7.4 %

Shares of BCTXW stock traded down $0.01 during trading hours on Friday, hitting $0.09. The company’s stock had a trading volume of 90,100 shares, compared to its average volume of 101,799. The company has a 50 day moving average of $0.13 and a 200 day moving average of $0.25. BriaCell Therapeutics has a 12-month low of $0.07 and a 12-month high of $1.70.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

Read More

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.